(Hypertension. 1997;29:177.)
© 1997 American Heart Association, Inc.
State-of-the-Art Lecture |
Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension
From the Department of Physiology, College of Medicine, University of Florida, Gainesville.
Correspondence to M. Ian Phillips, Department of Physiology, College of Medicine, Box 100274, University of Florida, Gainesville, FL 32610-0274. E-mail MIP{at}phys.med.ufl.edu
Antisense oligodeoxynucleotides have been designed to inhibit the production of specific proteins. In models of hypertension, we have targeted the renin-angiotensin system at the level of synthesis (angiotensinogen) and the receptor (AT1 receptor). The design of antisense oligonucleotides requires choosing a site to inhibit mRNA processing or translation. The strategy we use is to make three oligonucleotides of antisense sequences, upstream and downstream from the AUG site and over the AUG site. The oligonucleotides are tested in a screening test. Antisense oligonucleotides to AT1-receptor mRNA and to angiotensinogen mRNA reduce blood pressure in spontaneously hypertensive rats when injected into the brain. They significantly reduce the concentration of the appropriate protein. The oligonucleotides are also effective when administered systemically. The decrease in blood pressure with antisense oligonucleotides delivered in blood or brain lasts 3 to 7 days. To prolong the action, direct injection of naked DNA and injection of DNA in liposome carriers have been tested. Viral vectors have been developed to deliver antisense DNA. The viral vectors available include retroviruses and adenovirus, but the adeno-associated virus (AAV) vector is the vector of choice for ultimate use in gene therapy. It offers safety because it is nonpathogenic, has longevity because it integrates into the genome, and has sufficient carrying capacity to carry up to 4.5 kb antisense or gene in a recombinant AAV. Using rAAV-antisense to AT1 mRNA, there is efficient transfection into cells and an inhibition of AT1 receptor number. In in vivo tests, rAAV-AS AT1-receptor when injected into the brains of SHR reduces blood pressure for more than 2 months. In young rats (3 weeks old), rAAV-AS AT1-receptor decreases blood pressure and slows the development of hypertension. While further experiments need to be done on dose-response relationships and on the cellular mechanisms of these effects, the results show the feasibility of AAV as a vector for antisense inhibition, which may ultimately be used in gene therapy for hypertension.
Key Words: antisense oligonucleotide • adeno-associated viral vector • AT1 receptor • angiotensin
Abbreviations: AAV = adeno-associated virus • AAV-AS = adeno-associated virus-antisense • Ang = angiotensin • AS-ODN = antisense oligodeoxynucleotide • AT = angiotensin type II • AVP = arginine vasopressin • CMV = cytomegalovirus • ITR = inverted terminal repeat • LTR = long-terminal repeat • ODN = oligodeoxynucleotide • paAo = plasmid for angiotensinogen antisense • paAT1 = plasmid for AT1-receptor antisense • PCR = polymerase chain reaction • rAAV = recombinant adeno-associated virus • rAAV-AS = recombinant adeno-associated virus-antisense • RAS = renin-angiotensin system • RT-PCR = reverse transcription-polymerase chain reaction • SHR = spontaneously hypertensive rats • TGF = transforming growth factor • TRH = thyrotropin-releasing hormone • VSMC = vascular smooth muscle cell • WKY = Wistar Kyoto rats • wtAAV = wild-type adeno-associated virus
This article has been cited by other articles:
 |
|
 |
|
  Z. Sun, M. Bello-Roufai, and X. Wang RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1880 - H1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Feng, X. Yue, H. Xia, S. M. Bindom, P. J. Hickman, C. M. Filipeanu, G. Wu, and E. Lazartigues Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II-Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor Downregulation Circ. Res., March 28, 2008; 102(6): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sakai, Y. Hirooka, H. Shigematsu, T. Kishi, K. Ito, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2159 - H2166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kikuchi, D. L. Harris, Y. Obara, T. Senoo, and N. C. Joyce p27kip1 Antisense-Induced Proliferative Activity of Rat Corneal Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1763 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xie, W. Bu, S. Bhatia, J. Hare, T. Somasundaram, A. Azzi, and M. S. Chapman The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy PNAS, August 6, 2002; 99(16): 10405 - 10410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Phillips, Y. Tang, K. Schmidt-Ott, K. Qian, and S. Kagiyama Vigilant Vector: Heart-Specific Promoter in an Adeno-Associated Virus Vector for Cardioprotection Hypertension, February 1, 2002; 39(2): 651 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Phillips Gene Therapy for Hypertension: The Preclinical Data Hypertension, September 1, 2001; 38(3): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Galli and M. I. Phillips Angiotensin II AT1A Receptor Antisense Lowers Blood Pressure in Acute 2-Kidney, 1-Clip Hypertension Hypertension, September 1, 2001; 38(3): 674 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Culman, J. Baulmann, A. Blume, and T. Unger Review: The renin-angiotensin system in the brain: an update Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 96 - 102. [PDF]
|
|
|
|
|
|
S. Kagiyama, A. Varela, M. I. Phillips, and S. M. Galli Antisense Inhibition of Brain Renin-Angiotensin System Decreased Blood Pressure in Chronic 2-Kidney, 1 Clip Hypertensive Rats Hypertension, February 1, 2001; 37(2): 371 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kimura, D. Mohuczy, X. Tang, and M. I. Phillips Attenuation of Hypertension and Heart Hypertrophy by Adeno-Associated Virus Delivering Angiotensinogen Antisense Hypertension, February 1, 2001; 37(2): 376 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chen, Y. C. Zhang, D. Li, M. I. Phillips, P. Mehta, M. Shi, and J. L. Mehta Protection against Myocardial Dysfunction Induced by Global Ischemia-Reperfusion by Antisense-Oligodeoxynucleotides Directed at beta 1-Adrenoceptor mRNA J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 722 - 727. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Lanneau, M. T. Bluet-Pajot, P. Zizzari, Z. Csaba, P. Dournaud, L. Helboe, D. Hoyer, E. Pellegrini, G. S. Tannenbaum, J. Epelbaum, et al. Involvement of the Sst1 Somatostatin Receptor Subtype in the Intrahypothalamic Neuronal Network Regulating Growth Hormone Secretion: An in Vitro and in Vivo Antisense Study Endocrinology, March 1, 2000; 141(3): 967 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Zhang, J. D. Bui, L. Shen, and M. I. Phillips Antisense Inhibition of {beta}1-Adrenergic Receptor mRNA in a Single Dose Produces a Profound and Prolonged Reduction in High Blood Pressure in Spontaneously Hypertensive Rats Circulation, February 15, 2000; 101(6): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Clare Zhang, B. Kimura, L. Shen, and M. I. Phillips New {beta}-Blocker : Prolonged Reduction in High Blood Pressure With {beta}1 Antisense Oligodeoxynucleotides Hypertension, January 1, 2000; 35(1): 219 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Tang, D. Mohuczy, Y. C. Zhang, B. Kimura, S. M. Galli, and M. I. Phillips Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2392 - H2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakamura, A. Moriguchi, R. Morishita, K. Yamada, T. Nishii, N. Tomita, M. Ohishi, Y. Kaneda, J. Higaki, and T. Ogihara Activation of the Brain Angiotensin System by In Vivo Human Angiotensin-Converting Enzyme Gene Transfer in Rats Hypertension, August 1, 1999; 34(2): 302 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Phillips Is Gene Therapy for Hypertension Possible? Hypertension, January 1, 1999; 33(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
|
|
D. Mohuczy, C. H. Gelband, and M. I. Phillips Antisense Inhibition of AT1 Receptor in Vascular Smooth Muscle Cells Using Adeno-Associated Virus-Based Vector Hypertension, January 1, 1999; 33(1): 354 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Wang, R. A. Felder, and R. M. Carey Selective Inhibition of the Renal Dopamine Subtype D1A Receptor Induces Antinatriuresis in Conscious Rats Hypertension, January 1, 1999; 33(1): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Yang, M. I. Phillips, Y. C. Zhang, B. Kimura, L. P. Shen, P. Mehta, and J. L. Mehta Critical Role of AT1 Receptor Expression After Ischemia/Reperfusion in Isolated Rat Hearts : Beneficial Effect of Antisense Oligodeoxynucleotides Directed at AT1 Receptor mRNA Circ. Res., September 7, 1998; 83(5): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Peng, B. Kimura, M. J. Fregly, and M. I. Phillips Reduction of Cold-Induced Hypertension by Antisense Oligodeoxynucleotides to Angiotensinogen mRNA and AT1-Receptor mRNA in Brain and Blood Hypertension, June 1, 1998; 31(6): 1317 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Dillon, R. S. Root-Bernstein, and D. D. Holsworth Augmentation of Aortic Ring Contractions by Angiotensin II Antisense Peptide Hypertension, March 1, 1998; 31(3): 854 - 860. [Abstract] [Full Text] [PDF]
|
|